The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Design of a first-in-human multicenter open-label study of ZW171, a mesothelin x CD3 targeting bispecific T-cell engager, in participants with advanced solid tumors: ZWI-ZW171-101.
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Alentis Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Biohaven Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Hookipa Biotech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Normunity (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sanofi (Inst); SeaGen (Inst); Synthekine (Inst); Takeda (Inst); Zai Lab (Inst)
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); ArriVent Biopharma (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); City of Hope (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Syndax (Inst); Systimmune (Inst); Taiho Oncology (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); Vividion Therapeutics (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
John Hamm
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Jazz Pharmaceuticals; Meda Pharmaceuticals; Novocure
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Beijing Avistone Biotechnology Co., Ltd. (Inst); BioNTech SE (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); BrightPath Biotheraputics (Inst); Bristol-Myers Squibb (Inst); Cancer Research and Biostatistics (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Dana-Farber Cancer Institute (Inst); Deciphera (Inst); DualityBio (Inst); EMD Serono (Inst); EpicentRx (Inst); Exact Sciences (Inst); F Hoffmann-LaRoche Ltd. (Inst); Five Prime Therapeutics (Inst); G1 Therapeutics (Inst); GBG Forschungs (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gynecologic Oncology Group (Inst); Halozyme (Inst); Immunicum (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); InhibRx (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Johnson & Johnson (Inst); Lantern Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Moffitt (Inst); National Surgical Adjuvant Breast and Bowel Project (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Novartis (Inst); OncoC4 (Inst); OncoMed (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Pronova (Inst); Regeneron (Inst); Regeneron (Inst); Roche (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); SWOG (Inst); Systimmune (Inst); Zymeworks (Inst)
 
Fiona Thistlethwaite
Consulting or Advisory Role - AstraZeneca; CytomX Therapeutics; Grey Wolf Therapeutics; Guidepoint Pharmacy; Immatics; Oncobayes (Inst); Scenic Biotech; T-Knife
Research Funding - Abbvie (Inst); Achilles Therapeutics (Inst); Adaptimmune (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Crescendo Bioscience (Inst); CytomX Therapeutics (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); NovalGen (Inst); Novartis (Inst); Nucana (Inst); Oxford VacMedix (Inst); Pfizer (Inst); Roche (Inst); RS Oncology (Inst); Sanofi (Inst); T-Knife (Inst); Takeda (Inst)
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; Arcus Ventures; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
Erin Schenk
Stock and Other Ownership Interests - Thetis Pharma
Honoraria - Beigeneius; Curio Science; Horizon CME; Ideology Health; Janssen; MECC Global Meetings; MJH Life Sciences; OncLive; OncLive/MJH Life Sciences; Regeneron
Consulting or Advisory Role - AstraZeneca; BioAtla; CDR-Life; G1 Therapeutics; Harpoon therapeutics; IDEOlogy Health; Janssen; Regeneron; Regeneron; Slingshot Insights; Takeda; The Scienomics Group; Thetis Pharma; Third Bridge; WC Communications
Travel, Accommodations, Expenses - AstraZeneca; CDR-Life
 
Jason Luke
Stock and Other Ownership Interests - Actym Therapeutics; Kanaph Therapeutics; NeoTX; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - Abbvie; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Hotspot Therapeutics; Incyte; Merck; Novartis; Onc.AI; Pfizer; Regeneron; Tempest Therapeutics; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Ikena Oncology (Inst); Immatics (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Numab (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Merck
 
Diana Hanna
Consulting or Advisory Role - AstraZeneca
Research Funding - Agenus (Inst); BeiGene (Inst); Dragonfly Therapeutics (Inst); Dragonfly Therapeutics (Inst); Geistlich Pharma (Inst); Genentech/Roche (Inst); Indaptus Therapeutics (Inst); Phanes Therapeutics (Inst); SpringWorks Therapeutics (Inst); Toray Industries (Inst); Xilio Therapeutics (Inst); Zymeworks (Inst)
 
Anna Minchom
Honoraria - GlaxoSmithKline; Janssen; Merck; Seagen; Takeda
Consulting or Advisory Role - AstraZeneca; Faron Pharmaceuticals; GlaxoSmithKline; Immutep; Janssen Oncology; Merck; MSD; Pfizer
Research Funding - Astex Pharmaceuticals (Inst); Merck (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Byoung Chul Cho
Employment - Yonsei University Health System
Leadership - J INTS BIO
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Amgen; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BeiGene; BMS; Boehringer Ingelheim; Bridgebio; CJ bioscience; Cyrus therapeutics; Cyrus therapeutics; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Guardant Health; Harpoon Therapeutics; J INTS Bio; Janssen; Kanaph Therapeutics; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Therapex Co., Ltd; Yuhan
Research Funding - AstraZeneca; Champions Oncology; CJ bioscience; Cyrus Therapeutics; Dong-A ST; GI Innovation; ImmuneOncia; J Ints Bio; Janssen; MSD; Therapex; Vertical Bio AG; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen; PearlRiver Bio GmbH
Other Relationship - DAAN Biotherapeutics
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Chong Kun Dang Pharmaceutical (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IMBdx (Inst); inno.N (Inst); Janssen (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst); Zymeworks (Inst)
 
Rebecca Kristeleit
Honoraria - Abbvie; Abbvie; AstraZeneca; Basilea Pharmaceutical; Celcuity; Clovis Oncology; Eisai; Genmab; GlaxoSmithKline; Incyte; Leucid Bio; Merck Sharp & Dohme; MSD Oncology; Pharma&; Regeneron; Roche/Genentech; Shattuck Labs; Tesaro
Consulting or Advisory Role - Basilea; Clovis Oncology
Travel, Accommodations, Expenses - Basilea; Clovis Oncology; MSD Oncology
 
Dmitriy Zamarin
Leadership - Accurius
Stock and Other Ownership Interests - Accurius; Calidi Biotherapeutics; ImmunOs Therapeutics
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Daiichi Sankyo/Lilly; Everest Medicine; Genentech/Roche; Gilead Sciences; Hervolution; Memgen; Miltenyi Biotec; Takeda; Xencor
Research Funding - AstraZeneca/MedImmune (Inst); Genentech (Inst); Merck (Inst); Synthekine (Inst)
Patents, Royalties, Other Intellectual Property - I hold a patent regarding the use of recombinant Newcastle Disease Virus (NDV) for cancer therapy. (Inst)
 
Catherine Davidson
No Relationships to Disclose
 
Joseph Woolery
Employment - Zymeworks
Stock and Other Ownership Interests - Zymeworks
 
Pranshul Chauhan
Employment - Zymeworks
Stock and Other Ownership Interests - Zymeworks
 
Martin Wermke
Honoraria - Amgen; BMS GmbH & Co. KG; Boehringer Ingelheim; GWT; Janssen; Lilly; Merck Serono; Merck Serono; Novartis; Pfizer; SYNLAB
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; ImCheck therapeutics; immatics; ISA Pharmaceuticals; Lilly; Novartis; PharmaMar; Regeneron; Tacalyx; Zymeworks
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GEMoaB; immatics; Iovance Biotherapeutics; Janssen Oncology; Merck Serono; Pfizer; Sanofi/Aventis